At Amneal we are committed to forming deep relationships with our customers and business partners as well as creating strong value throughout the supply chain. That's why we've created this website. Get to know Amneal, as a company, partner, supplier, employer or customer. At amneal.com we provide valuable information about our operations, leaders, products, business principles and more… as well as details on how to get in touch with us.
Welcome to Amneal Pharmaceuticals—generic's new generation. We encourage you to learn more about our remarkable company. Explore our site.
News and Press
DRUGMAKERS TO FDA: CAN YOU SPEED IT UP? AMNEAL, PROVIDERS PAYING THE PRICE OF THE APPROVAL BACKLOG
A deep backlog at the U.S. Food and Drug Administration is delaying approvals for thousands of generic drugs, including roughly 100 applications posted by a Long Island drugmaker.
AMNEAL APPOINTS ROCHELLE FUHRMANN NEW CHIEF FINANCIAL OFFICER
Amneal Pharmaceuticals LLC is pleased to announce that Rochelle Fuhrmann has joined the fast-growing generics manufacturer as Chief Financial Officer. Ms. Fuhrmann was most recently Senior Vice President, Finance at Warner Chilcott plc. She was responsible for the oversight and direction of the finance and accounting functions including corporate accounting, financial planning and analysis, tax, treasury, risk management, and internal audit as well as investor relations.
AMNEAL ANNOUNCES LAUNCH OF ESOMEPRAZOLE STRONTIUM 49.3 mg DELAYED-RELEASE CAPSULES AUTHORIZED GENERIC
Bridgewater, NJ (USA),
January 6, 2014 – Amneal Pharmaceuticals LLC today announced the launch of generic Esomeprazole strontium delayed-release capsules 49.3 mg. This new esomeprazole therapy is the generic equivalent of the recently launched brand Esomeprazole strontium.